Anti-HER2 (human epidermal growth factor receptor 2) monoclonal antibody Trastuzumab revolutionized treatment of breast cancers that have ERBB2/HER2 gene amplification (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf). Here, ERBB2 is linked to breast carcinoma.